Related Experiment Video
Updated: Jul 30, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Evaluating anticancer potentials of potentized preparations in an in-vivo xenograft model
Rajesh Shah1, Gitanjali Talele1, Nirmal Kumar Kasinathan2
1Department of Research, Biosimilia Private Limited, Mumbai, India.
Background:
Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses.
Objectives:
In this research, potentized preparations derived from biomaterial, referred to as nosodes, have exhibited promising effectiveness against cancer in laboratory experiments. This study seeks to further substantiate these findings by employing animal models.
Method:
Potentized preparations from category nosodes sourced from biomaterials of HIV, Cancer tissue, Hepatitis C and a combination underwent testing within the NCI's preclinical evaluation protocols using Xenograft models (HOP62). All the experimental mice were randomly assigned to one of six groups (n = 6), including vehicle and positive controls. These preparations were administered orally at a dosage of 0.1 ml, five days a week, over a four-week period. The mice were closely monitored at regular intervals for 32 days, with observations regarding changes in body weight, tumor volume, morbidity, and mortality. Relative tumor volume (RTV) was calculated as the tumor volume on the day of measurement divided by the tumor volume on day 1.
Results:
The groups treated with Hepatitis C 30c and HIV 100c nosodes have not shown effect with respect to Relative Tumor Volume (RTV). Evidence of significant tumor regression was observed for RTV on day 30 in groups treated with HIV nosode 30c (P = 0.002), and Cancer nosode 30c (P = 0.005). Percentage Survival was noted better in HIV nosode 30c treated group from day 25, however, in other groups survival percentage remained constant. Varied animal body weight in all groups was noted. Significant differences in tumor volume with respect to time in all treated groups were observed.
Conclusion:
Results are suggestive of tumor regression which is encouraging to undertake further clinical trials to explore the anticancer potential of HIV nosode and Cancer nosode.
Insights
Potentized nosodes derived from HIV and cancer biomaterials showed significant tumor regression in mice. Further clinical trials are recommended to explore their anticancer potential.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Xenograft models in immunodeficient mice are crucial for preclinical anti-cancer drug testing.
- These models offer a cost-effective alternative to traditional animal studies, providing data for clinical trials.
- The study followed the National Cancer Institute's (NCI) Developmental Therapeutics Program protocols.
Purpose of the Study:
- To evaluate the anti-cancer effectiveness of potentized nosodes derived from biomaterials.
- To substantiate previous laboratory findings using animal models.
- To investigate the therapeutic responses of specific nosodes (HIV, Cancer, Hepatitis C) in a xenograft model.
Main Methods:
- Potentized nosodes from HIV, Cancer, and Hepatitis C biomaterials were tested using NCI preclinical evaluation protocols and Xenograft models (HOP62).
- Mice (n=6 per group) were randomly assigned to vehicle control, positive control, or treatment groups.
- Preparations were administered orally (0.1 ml) five days/week for four weeks, with monitoring for 32 days.
Main Results:
- HIV 30c and Cancer 30c nosodes demonstrated significant tumor regression (P<0.005).
- HIV 30c nosode treatment showed improved survival rates from day 25.
- Hepatitis C 30c and HIV 100c nosodes did not significantly affect tumor volume.
Conclusions:
- The observed tumor regression suggests potential anticancer properties of HIV and Cancer nosodes.
- Further clinical trials are warranted to explore the therapeutic efficacy of these nosodes.
- The study provides a basis for investigating novel homeopathic-based cancer therapies.
More Related Videos
07:10Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells
Published on: July 29, 2016
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
